Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

181. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. (PubMed)

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk.This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU) versus placebo

Full Text available with Trip Pro

2010 Cochrane

182. Review: low molecular weight heparin reduces risk of venous thromboembolism in adults with leg immobilisation

Review: low molecular weight heparin reduces risk of venous thromboembolism in adults with leg immobilisation Review: low molecular weight heparin reduces risk of venous thromboembolism in adults with leg immobilisationCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: low molecular weight heparin reduces risk of venous thromboembolism in adults with leg immobilisationCommentary Article Text Treatment Review: low molecular

2010 Evidence-Based Nursing

183. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial (PubMed)

Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial In ISAR-REACT 3, 30-day outcomes in 4570 biomarker negative patients undergoing percutaneous coronary intervention (PCI) > or =2 h after pre-treatment with 600 mg of clopidogrel revealed less bleeding with bivalirudin compared with unfractionated heparin, but no difference in 30-day net clinical benefit. The objective (...) of the present analysis was to assess the impact of bivalirudin vs. heparin on 1-year outcomes in ISAR-REACT 3.The primary outcome for this analysis was the composite of death, myocardial infarction, or target vessel revascularization 1 year after randomization. The composite of death or myocardial infarction was a secondary outcome. At 1 year, the primary outcome occurred in 17.1% of patients assigned to bivalirudin vs. 17.5% assigned to heparin [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.86

Full Text available with Trip Pro

2010 EvidenceUpdates

184. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin (PubMed)

Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin Thromboembolic disease is a common complication of total hip arthroplasty. The purpose of this study was to compare a new mobile compression device with low-molecular-weight heparin with regard to their safety and effectiveness for the prevention of venous thromboembolic disease.Patients who had a total hip arthroplasty were randomized (...) to receive prophylaxis with a mobile compression device or low-molecular-weight heparin for ten days. Use of the compression device began intraoperatively, and the patients in this group could receive 81 mg of aspirin daily after the surgery. The first injection of the low-molecular-weight heparin began between twelve and twenty-four hours after the surgery. After ten to twelve days, all patients underwent bilateral lower-extremity duplex ultrasonography to screen for deep venous thrombi in the calf

2010 EvidenceUpdates

185. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression (PubMed)

Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression The combination of heparin and aspirin was regarded as the 'standard therapy' for patients with recurrent pregnancy loss (RPL) and positive aPL antibodies to enhance live births, but it largely stems from expert opinion. We performed a meta-analysis (...) of randomized controlled trials (RCTs) to assess whether this combination works better than aspirin alone.RCTs testing the efficacy of a combination of heparin and aspirin vs aspirin alone in patients with RPL and positive aPL antibodies were identified in electronic databases. Random effect meta-analysis was employed to pool relative risks (RRs) (with 95% CI) of live births as the primary outcome. RRs of obstetrical complications and standardized mean difference of birth weight were the secondary outcomes

Full Text available with Trip Pro

2010 EvidenceUpdates

186. Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis (PubMed)

Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis The risk of postoperative venous thromboembolic disease is as high as 30%, with an associated fatality risk of 1%. Therefore, prophylaxis is essential, but the optimal regimen remains controversial. This study was designed to systematically review and quantitatively summarize the impact of mechanical compression versus subcutaneous heparin on venous (...) thromboembolic disease and posttreatment bleeding in postsurgical and posttrauma patients.Computerized searches of the MEDLINE and EMBASE databases through November 2008 were performed and supplemented with manual searches. We included studies that had: (1) a patient population undergoing surgery or admitted immediately posttrauma, (2) a randomized comparison of prophylaxis with mechanical compression versus subcutaneous heparin, (3) outcome measured in terms of deep vein thrombosis (DVT), pulmonary embolism

2010 EvidenceUpdates

187. WITHDRAWN: Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). (PubMed)

WITHDRAWN: Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Venous thromboembolic disease has been extensively studied in surgical patients. The benefit of thromboprophylaxis is now generally accepted, but it is medical patients who make up the greater proportion of the hospital population. Medical patients differ from surgical patients with regard to their health and the pathogenesis of thromboembolism and the impact (...) that preventative measures can have. The extensive experience from thromboprophylaxis studies in surgical patients is therefore not necessarily applicable to non-surgical patients.To determine the effectiveness and safety of heparin thromboprophylaxis in general medical patients.The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched 24 April 2009) and the Cochrane Central Register of Controlled Trials in The Cochrane Library (last searched Issue 2, 2009)We

2010 Cochrane

188. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. (PubMed)

Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. Aspirin and low-molecular-weight heparin are prescribed for women with unexplained recurrent miscarriage, with the goal of improving the rate of live births, but limited data from randomized, controlled trials are available to support the use of these drugs.In this randomized trial, we enrolled 364 women between the ages of 18 and 42 years who had a history of unexplained recurrent miscarriage and were attempting

2010 NEJM

189. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. (PubMed)

Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. The optimal unfractionated heparin regimen for percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndromes treated with fondaparinux is uncertain.To compare the safety of 2 unfractionated heparin regimens during PCI in high-risk patients with non-ST-segment elevation (...) acute coronary syndromes initially treated with fondaparinux.Double-blind randomized parallel-group trial in 179 hospitals in 18 countries involving 2026 patients undergoing PCI within 72 hours, nested within a cohort of 3235 high-risk patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux enrolled from February 2009 to March 2010.Patients received intravenously either low-dose unfractionated heparin, 50 U/kg, regardless of use of glycoprotein IIb/IIIa

Full Text available with Trip Pro

2010 JAMA

190. Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis

Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis Eppsteiner RW, Shin JJ, Johnson J, van Dam RM CRD summary This review found (...) that the risk of thromboembolic disease was similar for mechanical compression and heparin, but heparin was associated with a greater risk of bleeding in postsurgical/post-trauma patients. These conclusions are supported by the data, but should be interpreted with some caution due to the possibility of publication bias and lack of details on some aspects of trial quality. Authors' objectives To determine the impact of mechanical compression compared with subcutaneous heparin on venous thromboembolic disease

2010 DARE.

191. Heparin for Acute Coronary Syndromes

Heparin for Acute Coronary Syndromes Heparin for Acute Coronary Syndromes – TheNNTTheNNT Heparin Given for Acute Coronary Syndromes (Unstable Angina, NSTEMI, STEMI) 25 for major bleeding In Summary, for those who took the heparin: Benefits in NNT None were helped (life saved) None were helped (preventing a nonfatal heart attack) 100% saw no benefit 0% were helped by being saved from death 0% were helped by preventing a nonfatal heart attack Harms in NNT 1 in 25 were harmed (major bleeding (...) tears in the innermost lining of the artery (the tears are caused by plaques poking through). The blood typically misinterprets these tears as bleeding and forms a clot where the tears are, clogging the artery. Heparin inhibits clotting which seems intuitively like it would help but by the time the patient has symptoms like chest pain a clot has already formed, so it's unclear how much this can help. In addition, anything that inhibits clotting can lead to bleeding. Eight randomized control trials

2010 theNNT

192. Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study (PubMed)

Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study The Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study demonstrated that enoxaparin was superior to unfractionated heparin (UFH) in preventing venous thromboembolism in patients with ischemic stroke and was associated with a small but statistically significant

Full Text available with Trip Pro

2010 EvidenceUpdates

193. Safety and efficacy of prolonged use of unfractionated heparin after percutaneous coronary intervention

Safety and efficacy of prolonged use of unfractionated heparin after percutaneous coronary intervention Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

194. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review.

Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

195. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism

Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

196. Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention (PubMed)

Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention Bivalirudin demonstrated similar efficacy but resulted in a lower rate of bleeding compared to unfractionated heparin (UFH) plus platelet glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention. It has not been clearly evaluated whether this can also be applied to patients with diabetes

2009 EvidenceUpdates

197. Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials

Thrombolysis Compared With Heparin for the Initial Treatment of Pulmonary Embolism: A Meta-Analysis of the Randomized Controlled Trials PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2009 PedsCCM Evidence-Based Journal Club

198. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial (PubMed)

Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single-center randomized controlled trial Sodium citrate has antibacterial and anticoagulant properties that are confined to the catheter when used as a catheter lock. Studies of its use as a catheter lock have suggested its efficacy in preventing infection and bleeding complications compared with sodium heparin.Open-label randomized controlled trial of 2 catheter locks to examine the hypothesis that sodium (...) citrate catheter locks will reduce catheter-related bacteremia and exit-site infection.232 consenting long-term hemodialysis patients in 4 satellite dialysis units to a large dialysis program with protocolized treatment and targets. All patients were using twin-catheter single-lumen Tesio-Caths (MedComp, Harleysville, PA).6 months' use of 46.7% sodium citrate (citrate) or 5% heparin (heparin) locked postdialysis in the dead space of the central venous catheter.Primary end point of catheter-related

2009 EvidenceUpdates

199. Unfractionated Heparin Therapy in Infants and Children (PubMed)

Unfractionated Heparin Therapy in Infants and Children Unfractionated heparin is frequently used in tertiary pediatric centers for the prophylaxis and treatment of thromboembolic disease. Recent evidence suggests that the clinical outcomes of unfractionated heparin therapy in children are poor, as determined by target-range achievement and adverse-event rates. These reports of poor outcomes may be related to an age-dependent mechanism of action of unfractionated heparin. Furthermore, several (...) published studies have indicated that unfractionated heparin-monitoring assays currently in clinical use have significant limitations that likely affect the safety and efficacy of anticoagulant management. This review summarizes the growing body of evidence suggesting that pediatric-specific recommendations for unfractionated heparin therapy management are required to improve clinical outcomes related to this commonly prescribed medication.

2009 EvidenceUpdates

200. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) (PubMed)

Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study) The primary aims of this study were to determine the effects of heparin on length of stay and change from baseline multiple organ dysfunction (MOD) score. Secondary objectives were to estimate the effects of heparin on 28-day all-cause mortality, and to determine the possible effect modification on 28-day all-cause mortality, in subgroups defined by site of infection and baseline values of Acute (...) Physiology and Chronic Health Evaluation II score, MOD score, and d-dimer.Randomized, double-masked, placebo-controlled, single-center clinical trial, testing low dose continuous infusion of unfractioned heparin (UFH) as complementary treatment for sepsis.Five hundred fifty bed University Hospital and referral center in Medellín, Columbia.Three hundred nineteen patients admitted at the emergency room with signs indicative of sepsis.Patients were randomly assigned to receive placebo or UFH (500 units/hour

2009 EvidenceUpdates